Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript February 25, 2025Fulcrum Therapeutics, Inc. misses on earnings expectations.
Fulcrum Therapeutics Inc. (FULC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Altium Capital Jacob Gottlieb | 0 | $0 | 0% | |
| 2. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.35 | 43,360 | 43,360 | 2024-03-04 | Filing | ||
| $13.00 | 1,923,076 | Large Shareholder | 11,609,704 | 2023-01-20 | Filing | |
| $7.80 | 58,369 | Large Shareholder | 9,686,628 | 2023-01-04 | Filing | |
| $7.03 | 122,334 | Large Shareholder | 9,628,259 | 2023-01-04 | Filing | |
| $5.99 | 4,089 | Large Shareholder | 9,505,925 | 2022-12-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.06 | 498 | 14,062 | 2025-05-08 | Filing | ||
| $7.76 | 236 | 11,571 | 2024-05-07 | Filing | ||
| $11.72 | 4,884 | 11,807 | 2024-03-08 | Filing | ||
| $3.31 | 210 | 15,992 | 2023-05-10 | Filing | ||
| $15.00 | 6,766 | Officer, Director | 499,864 | 2023-01-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,710,697 | $13,566,809 | 0% | |
| 2. | 3,220,378 | $9,274,689 | 0% | |
| 3. | 402,600 | $1,159,488 | 0% | |
| 4. | 381,359 | $1,098,314 | 0% | |
| 5. | 279,812 | $805,859 | 0% |
News See All
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions].
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum Therapeutics' First Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Fulcrum Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.44.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Fulcrum Therapeutics Second Quarter 2023 Financial Results and Business Update Conference Call. Currently all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Fulcrum Therapeutics First Quarter 2023 Financial Results and Business Update Conference Call. Currently all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2022 Earnings Call Transcript
Operator: Greetings, and welcome to Fulcrum Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. As a reminder, this conference is being recorded.
Hedge Fund and Insider Trading News: Bill Ackman, Anthony Scaramucci, Ken Griffin, Skylar Capital Management, K2 Advisors, First Financial Bankshares Inc (FFIN), Deciphera Pharmaceuticals, Inc. (DCPH), and More
Pershing Square CEO Bill Ackman said Hindenburg Research’s report about Gautam Adani’s corporate empire Adani Group is "highly credible" and "extremely well-researched".
Billionaire Hedge Funds
